Zhang Honglai, Wu Jianguo, Keller Jill M, Yeung Kam, Keller Evan T, Fu Zheng
University of Michigan Comprehensive Cancer Center and Department of Urology, University of Michigan Health System, Ann Arbor, MI 48109, USA.
Cell Physiol Biochem. 2012;30(6):1340-50. doi: 10.1159/000343323. Epub 2012 Oct 23.
BACKGROUND/AIMS: Raf kinase inhibitory protein (RKIP) is a scaffolding molecule in the PEBP family that sequesters certain signaling molecules away from their pathways, thereby abrogating intracellular growth signals. RKIP has been assigned multiple functions and is associated with an increasing number of diseases through its involvement with signal transduction pathways. We previously demonstrated that RKIP is highly expressed in human normal prostate epithelial cells and plays a pivotal role during prostate cancer (PCa) progression. Whether RKIP is subject to endocrine regulation has not been reported.
The effect of dihydrotestosterone (DHT) on RKIP expression in normal prostate epithelial cells was determined by real-time RT-PCR and Western blot. Report assay was performed to determine whether the regulation of RKIP by androgens is at the transcriptional level. The binding of androgen receptor (AR) to the RKIP promoter was determined by EMSA and Chromatin Immunoprecipitation (ChIP) assays. To determine whether RKIP was regulated by androgen in vivo, we examined RKIP expression level in response to castration in 6-8 week old C57BL/6 male mice.
Here we report that DHT positively regulates the transcription of RKIP in the normal prostate epithelial cells. The anti-androgen bicalutamide blocked androgen-mediated regulation of RKIP, which indicates that this regulation is mediated through AR. Transfection of the cells with a RKIP promoter-driven luciferase reporter vector showed that DHT increased RKIP promoter activity in parallel with changes in expression. EMSA demonstrates that AR binds to a putative ARE in the RKIP promoter, which was further validated by ChIP assay. Importantly, these data are further supported by our in vivo experiment where castrated mice had less RKIP expression in their prostate glands than sham-operated mice.
Collectively, the results establish RKIP as a novel androgen target gene. Androgens induce RKIP expression through AR-mediated transcriptional modulation of the RKIP promoter in the prostate. This is the first demonstration of endocrine regulation of the metastasis suppressor gene RKIP.
背景/目的:Raf激酶抑制蛋白(RKIP)是磷脂酰乙醇胺结合蛋白(PEBP)家族中的一种支架分子,它能使某些信号分子脱离其信号通路,从而消除细胞内生长信号。RKIP具有多种功能,并且通过参与信号转导通路与越来越多的疾病相关。我们之前证明RKIP在人正常前列腺上皮细胞中高表达,并在前列腺癌(PCa)进展过程中起关键作用。RKIP是否受内分泌调节尚未见报道。
通过实时逆转录-聚合酶链反应(RT-PCR)和蛋白质免疫印迹法检测二氢睾酮(DHT)对正常前列腺上皮细胞中RKIP表达的影响。进行报告基因检测以确定雄激素对RKIP的调节是否在转录水平。通过电泳迁移率变动分析(EMSA)和染色质免疫沉淀(ChIP)试验确定雄激素受体(AR)与RKIP启动子的结合情况。为了确定RKIP在体内是否受雄激素调节,我们检测了6-8周龄C57BL/6雄性小鼠去势后RKIP的表达水平。
在此我们报道DHT正向调节正常前列腺上皮细胞中RKIP的转录。抗雄激素药物比卡鲁胺阻断了雄激素介导的RKIP调节,这表明这种调节是通过AR介导的。用RKIP启动子驱动的荧光素酶报告载体转染细胞显示,DHT增加RKIP启动子活性,且与表达变化平行。EMSA表明AR与RKIP启动子中一个假定的雄激素反应元件(ARE)结合,ChIP试验进一步证实了这一点。重要的是,我们的体内实验进一步支持了这些数据,即去势小鼠前列腺中RKIP的表达低于假手术小鼠。
总体而言,这些结果确立了RKIP作为一种新的雄激素靶基因。雄激素通过AR介导的对前列腺中RKIP启动子的转录调节来诱导RKIP表达。这是转移抑制基因RKIP受内分泌调节的首次证明。